Radius Health Inc. (NASDAQ:RDUS) shares rose 3.8% during trading on Thursday . The company traded as high as $43.39 and last traded at $42.98, with a volume of 347,583 shares trading hands. The stock had previously closed at $41.39.

RDUS has been the topic of a number of research analyst reports. Zacks Investment Research lowered Radius Health from a “hold” rating to a “sell” rating in a report on Monday, May 9th. Goldman Sachs Group Inc. initiated coverage on Radius Health in a report on Wednesday, March 30th. They set a “neutral” rating and a $37.00 price target on the stock. Canaccord Genuity reissued a “buy” rating on shares of Radius Health in a report on Tuesday, May 31st. Cowen and Company initiated coverage on Radius Health in a report on Friday, May 6th. They set an “outperform” rating on the stock. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $70.00 price target on shares of Radius Health in a report on Thursday, March 31st. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $70.07.

The company’s market capitalization is $1.95 billion. The firm’s 50-day moving average price is $38.24 and its 200-day moving average price is $35.40.

Radius Health (NASDAQ:RDUS) last announced its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by $0.20. During the same quarter last year, the business earned ($0.47) earnings per share. The business’s quarterly revenue was up .0% on a year-over-year basis. Equities research analysts expect that Radius Health Inc. will post ($3.71) earnings per share for the current fiscal year.

A number of hedge funds recently made changes to their positions in RDUS. Dimensional Fund Advisors LP bought a new stake in shares of Radius Health during the fourth quarter valued at approximately $1,362,000. Nationwide Fund Advisors raised its stake in shares of Radius Health by 1.8% in the fourth quarter. Nationwide Fund Advisors now owns 24,238 shares of the biopharmaceutical company’s stock valued at $1,492,000 after buying an additional 437 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Radius Health by 12.8% in the fourth quarter. Rhumbline Advisers now owns 31,671 shares of the biopharmaceutical company’s stock valued at $1,949,000 after buying an additional 3,585 shares in the last quarter. Swiss National Bank raised its stake in shares of Radius Health by 1.7% in the fourth quarter. Swiss National Bank now owns 36,100 shares of the biopharmaceutical company’s stock valued at $2,222,000 after buying an additional 600 shares in the last quarter. Finally, Mutual of America Capital Management LLC raised its stake in shares of Radius Health by 18.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 36,483 shares of the biopharmaceutical company’s stock valued at $2,245,000 after buying an additional 5,683 shares in the last quarter.

Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.